Welcome to the BRACE trial
This Australian-led study is the world’s largest trial on the off-target effects of Bacille Calmette-Guérin (BCG) vaccine. More than 6800 healthcare workers have been enrolled in Australia, Brazil, Spain, the Netherlands and the United Kingdom.
In addition to preventing severe tuberculosis (TB) in children, BCG vaccine has off-target (non-specific or immunomodulatory) effects. That’s why this multi-centre, randomised controlled clinical trial is working to determine:
As the research team prepares for analysis, trial data generated so far includes:
- Trial Symptom Tracker app entries – 337,000
- Telephonista entries – 78,000
- BRACE blood samples – 20,000
- BCOS blood samples – 1600
- Clinic visits – 21,000
- Surveys sent – 22,000
The BRACE trial goes global
Hear from Professor Nigel Curtis, Chief Principal Investigator of the BRACE trial, as he discusses whether BCG vaccine might protect healthcare workers against COVID-19.
BRACE COVID-19-Specific vaccine sub-study (BCOS)
The BRACE trial has introduced a sub-study at selected sites in Australia and Brazil to investigate whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 disease or COVID-19-specific vaccination. The sub-study will look at whether BCG vaccine, by boosting the immune system, improves the response to Pfizer, AstraZeneca and CoronaVac vaccines.
BRACE biosample and laboratory lead, Dr Nicole Messina, receives NHMRC Ideas Grant
MCRI’s BCG vaccine trial joins global race to better understand COVID-19 variants
Could BCG vaccine protect against COVID-19? UK recruitment begins